Technical Analysis for PHAR - Pharming Group N.V.

Grade Last Price % Change Price Change
F 11.37 2.43% 0.27
PHAR closed up 2.43 percent on Thursday, July 29, 2021, on 9 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical PHAR trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
20 DMA Resistance Bearish 2.43%
Outside Day Range Expansion 2.43%
Fell Below 20 DMA Bearish 1.70%
180 Bearish Setup Bearish Swing Setup 1.70%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.44%
Crossed Above 20 DMA Bullish -0.44%
MACD Bullish Signal Line Cross Bullish -0.44%
Narrow Range Bar Range Contraction -0.44%
Older End-of-Day Signals for PHAR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pharming Group N.V. Description

Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.


Classification

Sector: Other
Industry: Other
Keywords: Life Sciences Biology Pharmaceutical Drug Discovery Biopharmaceutical Products Angioedema Hereditary Angioedema Complement System Acute Kidney Injury Complement Deficiency Haemophilia C1 Inhibitor Pharming

Is PHAR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.99
52 Week Low 10.8
Average Volume 2,905
200-Day Moving Average 0.00
50-Day Moving Average 11.83
20-Day Moving Average 11.31
10-Day Moving Average 11.21
Average True Range 0.28
ADX 18.03
+DI 27.66
-DI 39.35
Chandelier Exit (Long, 3 ATRs) 10.89
Chandelier Exit (Short, 3 ATRs) 11.64
Upper Bollinger Bands 11.81
Lower Bollinger Band 10.81
Percent B (%b) 0.56
BandWidth 8.87
MACD Line -0.18
MACD Signal Line -0.22
MACD Histogram 0.0404
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.37
Resistance 3 (R3) 11.37 11.37 11.37
Resistance 2 (R2) 11.37 11.37 11.37 11.37
Resistance 1 (R1) 11.37 11.37 11.37 11.37 11.37
Pivot Point 11.37 11.37 11.37 11.37 11.37
Support 1 (S1) 11.37 11.37 11.37 11.37 11.37
Support 2 (S2) 11.37 11.37 11.37 11.37
Support 3 (S3) 11.37 11.37 11.37
Support 4 (S4) 11.37